Genmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 138.44% from the company’s previous close.

A number of other analysts also recently issued reports on GMAB. Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB stock opened at $20.97 on Thursday. The company has a market capitalization of $13.88 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 0.59 and a beta of 0.97. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company’s fifty day moving average price is $21.07 and its 200-day moving average price is $23.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the firm posted $0.47 earnings per share. Equities research analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the period. R Squared Ltd purchased a new position in shares of Genmab A/S during the 4th quarter worth about $93,000. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.